MA46750A - Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents - Google Patents

Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Info

Publication number
MA46750A
MA46750A MA046750A MA46750A MA46750A MA 46750 A MA46750 A MA 46750A MA 046750 A MA046750 A MA 046750A MA 46750 A MA46750 A MA 46750A MA 46750 A MA46750 A MA 46750A
Authority
MA
Morocco
Prior art keywords
ralinepag
agents
combinations
methods
treating pah
Prior art date
Application number
MA046750A
Other languages
English (en)
Inventor
John W Adams
Dominic P Behan
Lucie H Clapp
Original Assignee
Arena Pharm Inc
Lucie H Clapp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Lucie H Clapp filed Critical Arena Pharm Inc
Publication of MA46750A publication Critical patent/MA46750A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA046750A 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents MA46750A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US201762530533P 2017-07-10 2017-07-10

Publications (1)

Publication Number Publication Date
MA46750A true MA46750A (fr) 2019-09-18

Family

ID=60451197

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046750A MA46750A (fr) 2016-11-10 2017-11-10 Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents

Country Status (11)

Country Link
US (2) US12377067B2 (fr)
EP (2) EP4681708A3 (fr)
JP (3) JP2019533713A (fr)
KR (4) KR102916884B1 (fr)
CN (2) CN119367341A (fr)
AU (3) AU2017357759A1 (fr)
CA (1) CA3043283A1 (fr)
ES (1) ES3052035T3 (fr)
IL (2) IL266518B1 (fr)
MA (1) MA46750A (fr)
WO (1) WO2018089804A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017357759A1 (en) 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents
KR20220119169A (ko) 2017-03-01 2022-08-26 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
JP7519909B2 (ja) * 2018-05-16 2024-07-22 アレーナ ファーマシューティカルズ，インク． Ｐｇｉ２－受容体アゴニストを含む組成物、およびその調製のためのプロセス
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
WO2020048299A1 (fr) * 2018-09-06 2020-03-12 广东东阳光药业有限公司 Co-cristal pharmaceutique et son procédé de préparation
DK3897646T3 (da) 2018-12-21 2024-07-01 Actelion Pharmaceuticals Ltd Macitentan til behandling af pulmonal arteriel hypertension
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
JP2025506098A (ja) 2022-02-15 2025-03-07 ユナイテッド セラピューティクス コーポレイション 結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (fr) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Derives fusionnes de l'acide benzeneoxyacetique
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (fr) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Compose biaryle, procede de production de ce compose, et principe actif
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
BR0211810A (pt) 2001-08-09 2004-08-24 Ono Pharmaceutical Co Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CA2755297A1 (fr) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Procedes de preparation de n-heteroaryl-n-aryl-amines par mise en reaction d'un ester d'acide n-aryl-carbamique avec un halo-heteroaryle, et procedess analogues
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
WO2006023844A2 (fr) 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
WO2007051255A1 (fr) 2005-11-04 2007-05-10 The University Of Sydney Procédé de synthèse de composés contenant un système azacyclique
WO2007133653A2 (fr) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Procédés de traitement de troubles sanguins
HRP20141209T2 (hr) 2008-03-18 2016-05-06 Arena Pharmaceuticals, Inc. Modulatori receptora prostaciklina (pgi2) korisni za liječenje poremećaja povezanih s time
SG171413A1 (en) 2008-11-26 2011-07-28 Arena Pharm Inc Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
US20120225937A1 (en) * 2009-09-23 2012-09-06 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pg12 receptor agonists
WO2013040068A2 (fr) 2011-09-12 2013-03-21 Irix Pharmaceuticals, Inc. Procédé de préparation de prostacyclines synthétiques
CN104822372A (zh) * 2012-11-30 2015-08-05 英斯梅德股份有限公司 前列环素组合物及其使用方法
EP4349330A3 (fr) 2014-10-23 2024-07-31 Arena Pharmaceuticals, Inc. Procédé de traitement d'états liés au récepteur pgi2
CN107427698A (zh) * 2015-01-13 2017-12-01 维瓦斯公司 肺高血压的组合疗法
AU2017357759A1 (en) 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents

Also Published As

Publication number Publication date
EP3538154B1 (fr) 2025-09-03
AU2023263497B2 (en) 2025-09-18
IL323354A (en) 2025-11-01
KR20200015439A (ko) 2020-02-12
US12377067B2 (en) 2025-08-05
EP4681708A2 (fr) 2026-01-21
EP4681708A3 (fr) 2026-03-18
IL266518B1 (en) 2026-01-01
ES3052035T3 (en) 2025-12-30
AU2017357759A1 (en) 2019-06-06
JP2019533713A (ja) 2019-11-21
US20190321328A1 (en) 2019-10-24
CN119367341A (zh) 2025-01-28
AU2023263497A1 (en) 2023-11-30
CA3043283A1 (fr) 2018-05-17
KR20260020212A (ko) 2026-02-10
US20260014114A1 (en) 2026-01-15
EP3538154A1 (fr) 2019-09-18
CN110691612A (zh) 2020-01-14
JP2025131627A (ja) 2025-09-09
JP2023029865A (ja) 2023-03-07
KR20240068077A (ko) 2024-05-17
WO2018089804A9 (fr) 2018-06-21
CN110691612B (zh) 2024-11-08
IL266518A (en) 2019-07-31
KR20230021186A (ko) 2023-02-13
KR102916884B1 (ko) 2026-01-22
AU2025283444A1 (en) 2026-01-15
AU2023263497C1 (en) 2026-01-22
WO2018089804A1 (fr) 2018-05-17

Similar Documents

Publication Publication Date Title
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
EP3226848A4 (fr) Méthodes de traitement de l'alopécie en aires à l'aide d'approches de modulation génique
EP3471780A4 (fr) Traitement de la dmla à l'aide d'un variant d'aav2 et d'aflibercept
EP3668500A4 (fr) Méthodes de traitement de l'arthrose à l'aide d'un gel de cannabidiol transdermique
MA46954A (fr) Méthodes de traitement d'états inflammatoires
ME03070B (fr) Méthodes pour le traitement d'infections virales à filoviridae
EP3436020A4 (fr) Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
MA42450A (fr) Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
EP3426286A4 (fr) Méthodes de traitement de l'hypophosphatasie chez l'enfant
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3519058C0 (fr) Compositions et méthodes de traitement des cheveux
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3426777A4 (fr) Vecteurs de combinaison et méthodes de traitement du cancer
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose